Co-Authors
This is a "connection" page, showing publications co-authored by Bart Lambrecht and Jean Yombi.
Connection Strength
0.164
-
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Dec 14; 21(1):1024.
Score: 0.057
-
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Nov 27; 21(1):981.
Score: 0.057
-
A CARD9 Founder Mutation Disrupts NF-?B Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation. Front Immunol. 2018; 9:2366.
Score: 0.050